Q32 Bio Inc. Common Stock (QTTB)

About QTTB

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

22

Website

www.q32bio.com/

Fundamentals

1-day range

$14.92$16.25

Market cap

$451.37M

P/E (trailing)

15.71

P/E (forward)

-14.74

EPS (trailing)

$2.29

Dividend yield

—

Beta

0.30

Avg. volume

1.16M

Forecasts

5 analyst ratings

Q32 Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• QTTB

  Q32 Bio Inc. Common Stock

  $15.01

  ▼ 7.06%
  Market cap $451.37MP/E 15.71
  $1.62$23.57
• SGMT

  Sagimet Biosciences Inc. Series A Common Stock

  $10.55

  ▼ 1.86%
  Market cap $441.53MP/E —
  $4.5$11.15
• PRTA

  Prothena Corporation plc Ordinary Shares

  $9.35

  ▲ 2.86%
  Market cap $436.10MP/E —
  $7.73$11.8
• BNTC

  Benitec Biopharma Inc. Common Stock

  $12.51

  ▼ 1.30%
  Market cap $417.41MP/E —
  $9.85$16.76
• KMDA

  Kamada Ltd. Ordinary Shares

  $8.29

  ▲ 0.36%
  Market cap $417.07MP/E 20.65
  $6.5$9.35
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $413.45MP/E —
  $2.72$6.42
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $398.42MP/E —
  $3.86$9.12

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34
  benzinga · 8/24/2026

Institutional Ownership

March 31, 2026

Total shares held

9.38M

Total value held

$58.95M

Institutional holders

51